248 related articles for article (PubMed ID: 35021019)
1. Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis.
Gabillard-Lefort C; Casey M; Glasgow AMA; Boland F; Kerr O; Marron E; Lyons AM; Gunaratnam C; McElvaney NG; Reeves EP
Am J Respir Crit Care Med; 2022 Apr; 205(7):783-794. PubMed ID: 35021019
[No Abstract] [Full Text] [Related]
2. Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis.
Jarosz-Griffiths HH; Scambler T; Wong CH; Lara-Reyna S; Holbrook J; Martinon F; Savic S; Whitaker P; Etherington C; Spoletini G; Clifton I; Mehta A; McDermott MF; Peckham D
Elife; 2020 Mar; 9():. PubMed ID: 32118580
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of hepatic stellate cell activation by extracellular ATP is dependent on P2X7R-mediated NLRP3 inflammasome activation.
Jiang S; Zhang Y; Zheng JH; Li X; Yao YL; Wu YL; Song SZ; Sun P; Nan JX; Lian LH
Pharmacol Res; 2017 Mar; 117():82-93. PubMed ID: 27940204
[TBL] [Abstract][Full Text] [Related]
4. The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.
Becq F; Mirval S; Carrez T; Lévêque M; Billet A; Coraux C; Sage E; Cantereau A
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34266939
[TBL] [Abstract][Full Text] [Related]
5. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
6. P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.
Khalafalla MG; Woods LT; Camden JM; Khan AA; Limesand KH; Petris MJ; Erb L; Weisman GA
J Biol Chem; 2017 Oct; 292(40):16626-16637. PubMed ID: 28798231
[TBL] [Abstract][Full Text] [Related]
7. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.
Shaughnessy CA; Zeitlin PL; Bratcher PE
Sci Rep; 2021 Oct; 11(1):19810. PubMed ID: 34615919
[TBL] [Abstract][Full Text] [Related]
8. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
Shaughnessy CA; Zeitlin PL; Bratcher PE
J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469
[TBL] [Abstract][Full Text] [Related]
9. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
Borgo C; D'Amore C; Capurro V; Tomati V; Sondo E; Cresta F; Castellani C; Pedemonte N; Salvi M
Cell Mol Life Sci; 2022 Mar; 79(4):192. PubMed ID: 35292885
[TBL] [Abstract][Full Text] [Related]
10. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
[No Abstract] [Full Text] [Related]
11. Activated human CD4+CD45RO+ memory T-cells indirectly inhibit NLRP3 inflammasome activation through downregulation of P2X7R signalling.
Beynon V; Quintana FJ; Weiner HL
PLoS One; 2012; 7(6):e39576. PubMed ID: 22768094
[TBL] [Abstract][Full Text] [Related]
12. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages.
Budai MM; Varga A; Milesz S; Tőzsér J; Benkő S
Mol Immunol; 2013 Dec; 56(4):471-9. PubMed ID: 23911403
[TBL] [Abstract][Full Text] [Related]
13. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
14. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.
Laselva O; Bartlett C; Gunawardena TNA; Ouyang H; Eckford PDW; Moraes TJ; Bear CE; Gonska T
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303536
[TBL] [Abstract][Full Text] [Related]
15. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E
Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793
[TBL] [Abstract][Full Text] [Related]
16. P2X7 Receptor-Induced Bone Cancer Pain by Regulating Microglial Activity via NLRP3/IL-1beta Signaling.
Wu P; Wu X; Zhou G; Wang Y; Liu X; Lv R; Liu Y; Wen Q
Pain Physician; 2022 Nov; 25(8):E1199-E1210. PubMed ID: 36375190
[TBL] [Abstract][Full Text] [Related]
17. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
18. CFTR modulator use in post lung transplant recipients.
Benninger LA; Trillo C; Lascano J
J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
[TBL] [Abstract][Full Text] [Related]
19. Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors.
Tapia Cáceres F; Gaspari TA; Hossain MA; Samuel CS
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806076
[TBL] [Abstract][Full Text] [Related]
20. Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
Saint-Criq V; Wang Y; Delpiano L; Lin J; Sheppard DN; Gray MA
J Cyst Fibros; 2021 Sep; 20(5):843-850. PubMed ID: 34020896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
